Legal & General Group
ECYT

Legal & General Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Legal & General Group’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,041
Closed -$178K – 3402
2018
Q3 		$178K Sell
10,041
-767
-7% -$13.2K ﹤0.01% 2360
2018
Q2 		$149K Buy
+10,808
New +$128K ﹤0.01% 2368
2017
Q2 		– Sell
-9,583
Closed -$23K – 3418
2017
Q1 		$23K Hold
9,583
– – ﹤0.01% 3047
2016
Q4 		$25K Buy
9,583
+2,750
+40% +$7.9K ﹤0.01% 3083
2016
Q3 		$21K Hold
6,833
– – ﹤0.01% 2811
2016
Q2 		$22K Hold
6,833
– – ﹤0.01% 2830
2016
Q1 		$23K Hold
6,833
– – ﹤0.01% 2654
2015
Q4 		$28K Hold
6,833
– – ﹤0.01% 2655
2015
Q3 		$30K Hold
6,833
– – ﹤0.01% 2648
2015
Q2 		$36K Hold
6,833
– – ﹤0.01% 2653
2015
Q1 		$42K Hold
6,833
– – ﹤0.01% 2567
2014
Q4 		$43K Hold
6,833
– – ﹤0.01% 2499
2014
Q3 		$44K Buy
+6,833
New +$46.7K ﹤0.01% 2462

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Legal & General Group's ECYT Position: Q4 2018 in Review

Legal & General Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 10,041 shares — an estimated $178K sold.

Legal & General Group first reported a position in ECYT in Q3 2014 and held it in 13 quarters. The position peaked at $178K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Legal & General Group reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Legal & General Group sold 10,041 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $178K.
  • Legal & General Group first reported a position in Endocyte, Inc. Common Stock in Q3 2014 and held it in 13 quarters.
  • Legal & General Group's Endocyte, Inc. Common Stock position peaked at $178K in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Legal & General Group's 13F filing for Q4 2018, filed 15 Feb 2019.